Restless Legs Syndrome
Central nervous system
Oxycodone hydrochloride/naloxone hydrochloride prolonged release tablets are not recommended for use as symptomatic treatment of patients with restless legs syndrome. Efficacy and safety data in support of Targinact® was not sufficient to allay concerns regarding;
- Safety issues and side effects associated with long term use of opioids
- The controlled drug status and potential for opioid abuse
- A lack of evidence for use beyond 1 year, uncertainty around the mechanism of action and potential for tolerance to develop when used to treat restless legs syndrome.
This colour classification is in agreement with the recommendations contained within both the NHS England and NHS Clinical Commissioners guidance document ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs‘ published in November 2017.
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria